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Abstract: Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with
prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-
induced changes in the walking pattern are still poorly understood but may provide a better understanding
of the mechanisms underlying the beneficial drug effects. 61 PwMS were treated with PR-fampridine in a
randomized, monocentric, double-blind and placebo-controlled clinical trial with crossover design (FAMP-
KIN). Drug-induced improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-
Minute Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced
changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during treadmill walk-
ing. Vertical ground reaction forces were analyzed during different gait phases. Kinetic data of 44 PwMS
was eligible for analysis. During double-blind treatment with PR-fampridine, patients performed signif-
icantly better in the T25FW and 6MWT than during placebo treatment (p < 0.0001 for both). At the
group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.
However, we found relevant changes of walking kinetics regarding forces during loading, single limb and
pre-swing phase in a patient sub-group (n = 8). Interestingly, this sub-group demonstrated superior
responsiveness to PR-fampridine in the clinical walking tests compared to those patients without any
fampridine-induced changes in kinetics (n = 36). Our results demonstrate fampridine-induced changes in
gait kinetics in a sub-group of PwMS. These gait pattern changes were accompanied by improved clinical
walking performance under PR-fampridine. These results shed some light on the biomechanical changes
in walking patterns underlying enhanced fampridine-induced gait performance.
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Abstract 
 
Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with 
prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. 
Associated fampridine-induced changes in the walking pattern are still poorly understood but 
may provide a better understanding of the mechanisms underlying the beneficial drug effects. 
61 PwMS were treated with PR-fampridine in a randomized, monocentric, double-blind and 
placebo-controlled clinical trial with crossover design (FAMPKIN). Drug-induced 
improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute 
Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced 
changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during 
treadmill walking. Vertical ground reaction forces were analyzed during different gait phases.  
Kinetic data of 44 PwMS was eligible for analysis. During double-blind treatment with PR-
fampridine, patients performed significantly better in the T25FW and 6MWT than during 
placebo treatment (p<0.0001 for both). At the group level (n=44), there were no significant 
changes of gait kinetics under PR-fampridine vs. placebo. However, we found relevant 
changes of walking kinetics regarding forces during loading, single limb and pre-swing phase 
in a patient sub-group (n=8). Interestingly, this sub-group demonstrated superior 
responsiveness to PR-fampridine in the clinical walking tests compared to those patients 
without any fampridine-induced changes in kinetics (n=36). 
Our results demonstrate fampridine-induced changes in gait kinetics in a sub-group of PwMS. 
These gait pattern changes were accompanied by improved clinical walking performance 
under PR-fampridine. These results shed some light on the biomechanical changes in walking 




Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) and 
the primary cause of persisting motor disability including impaired walking function and 
mobility in young adults.1  
Treatment with prolonged-release (PR) fampridine (4-aminopyridine, dalfampridine) improves 
MS-associated gait disorders.2,3 4-aminopyridine is a potassium channel blocker enhancing 
signal conduction in demyelinated nerve fibers.4 Treatment with prolonged-release (PR) 
fampridine results in enhanced walking speed, endurance as well as improved balance and 
self-perceived walking function.5-11 Whereas the effects of PR-fampridine on clinical walking 
performance are well investigated, only little information exists on drug-induced modifications 
of the gait pattern that might underlie the improvement in walking capacity.  
Instrumented gait analysis based on kinematic (i.e. quantification of movements) or kinetic 
(i.e. quantification of forces during motion) techniques enables an objective and 
comprehensive quantification of walking quality. To date, the effects of PR-fampridine on MS-
related pathologies of the gait pattern are poorly understood.3 Previous data demonstrated 
fampridine-induced changes of gait kinematics: these changes were heterogeneous across 
patients, but correlated with improvements in clinical walking tests.11 In contrast to cost- and 
time-intensive full body kinematics, kinetic gait analysis is an easily applicable, fast, and widely 
used technique in research and clinical settings that has demonstrated high sensitivity in 
describing MS-associated walking impairments.12-15  
This study aimed at characterizing fampridine-induced changes in gait patterns of PwMS using 
pressure-based kinetic foot print analysis. In a second step, the study investigated the 
influence of drug-induced changes in gait kinetics on patients' clinical walking performance 
(i.e. gait speed, endurance), thus trying to shed some light onto the locomotor mechanisms 






This study (FAMPKIN; clinicaltrials.gov; NCT01576354) was performed at the University 
Hospital Zurich. Sixty-one subjects with MS defined by the McDonald criteria (disease duration 
> 3 months)16 with a clinically apparent walking impairment were analyzed. Patients unable to 
walk a distance of at least 50 meters within a period of 6 minutes (with or without assistive 
devices) were excluded. Further inclusion and exclusion criteria are described elsewhere.11 
All participants gave written informed consent. The study was approved by the Zurich cantonal 
ethics committee. All experimental procedures were performed according to the Declaration 
of Helsinki and the Good Clinical Practice guidelines. The present manuscript describes 
results of a sub-study (gait kinetics) performed within the framework of the FAMPKIN trial.  
 
Study design 
This monocentric, phase II study was conducted as randomized, placebo-controlled, double-
blind trial with crossover design (Figure 1A).11 An initial screening visit was followed by a 2-
week run-in phase with single-blind placebo treatment. Afterwards, patients were randomized 
into two groups, one of which was treated with PR-fampridine (Biogen, Cambridge, MA) first 
(for 6 weeks), the other received placebo (Biogen, Cambridge, MA) in a double-blind fashion. 
Treatment was changed after a two-week wash-out period (i.e. single-blind placebo treatment) 
between visit 6 and 7. PR-fampridine and placebo tablets were taken orally twice daily (12h 
apart). Patients did not receive any study medication for the last two weeks of the trial (follow-
up). All experimenters and patients were blinded to the treatment allocation at the time of 
assessment. Blinding and randomization was conducted by the Zurich cantonal pharmacy.    
 
Outcome measures 
Maximal walking speed (timed 25-foot walk; T25FW)17 and walking endurance (6-minute 
walking test; 6MWT)18 were used as core clinical outcome measures19 and were assessed at 
all double-blind visits (V3-6 and V8-11).11 Assistive walking devices were used as required 
during clinical walking tests. The usage of particular walking aids (i.e. walking sticks, crutches, 
walking frames) were kept identical for all walking tests of a given individual during the trial. 
Treadmill-based kinetic gait analysis was performed at two visits during each treatment phase 
(V4/V6, V9/V11). If required, subjects were allowed to hold on the handrails during walking. 
An instrumented treadmill with integrated pressure plate (FDMTHM-M-2i System, zebris 
Medical GmbH, Germany) was used to measure vertical ground reaction forces during 
walking.11 Walking conditions (i.e. walking speed, use of handrails etc.) were kept constant 
across all visits of the trial, thus enabling a precise comparison of drug effects on ambulatory 
function. Prior to kinetic analysis, all patients were familiarized with treadmill walking to assure 
a stable walking pattern.20 Walking speed for each patient was fixed at half-maximal gait 
velocity (v50%) as determined by the T25FW, thus adjusting gait speed to the individual 
impairment level (regarding walking speed).11,21,22 Patients were analyzed while walking 
barefoot for >30 seconds on the treadmill.  
 
Data analysis 
Results of the T25FW, 6MWT and kinetic gait analysis were assessed during the double-blind 
treatment phases with PR-fampridine and placebo and were expressed as change under PR-
fampridine compared to placebo performance.  
Kinetic parameters were assessed per gait cycle which was defined as time interval between 
two consecutive heel strikes of the same leg. The stance phase was divided into three sub-
phases being defined as initial loading phase, single stance phase and pre-swing (i.e. push 
off) phase. Loading phase was defined between the initial contact of the ipsilateral foot and 
toe off of the contralateral foot. This phase corresponds to the pre-swing phase of the 
contralateral foot (i.e. interval between the initial contact of the contralateral foot and the last 
contact of the ipsilateral foot). Single stance phase was defined as period during which only 
one foot contacts the floor.  
Kinetic data during the different gait phases were expressed as averaged values and as 
summated value over the respective phases. Summated values were used to obtain 
information concerning the cumulative force applied during the particular gait phase. The more 
impaired leg of each patient was determined by neurological examination as described 
previously.11 To avoid confounding effects of changing body weight on kinetic analysis, 
pressure data of each patient was normalized to his respective body weight at each single 
visit. This normalization allowed for comparisons of kinetic data between different visits and 
patients.  
To further assess the impact of fampridine-induced changes in gait kinetics on improvements 
in clinical walking function (i.e. the T25FW, 6MWT), participants were divided into two sub-
groups, one of which containing patients without any fampridine-induced changes in gait 
kinetics (no kinetic adaptations, NKA group). The second sub-group (kinetic adaptations; KA 
group) consisted of patients revealing at least one relevant change in any kinetic parameter 
(see definition below) under PR-fampridine relative to placebo treatment (Figure 1B). 
 
Statistical analysis 
Statistical analysis was performed by SPSS (V23, SPSS Inc., CA, USA) and Matlab 
(Mathworks, Inc., USA). 
Demographic differences between the two sub-groups (i.e. NKA vs. KA group: Table 1) were 
assessed by unpaired, two-tailed t-test (age, disease duration), Mann-Whitney test (expanded 
disability status scale (EDSS) score), Fisher’s Exact test (gender) and Pearson Chi-Square 
test (MS type). Differences in kinetic gait parameters and clinical gait tests between the 
double-blind treatment phases were analyzed by paired, two-tailed t-tests. Statistical 
comparisons were followed by Bonferroni post-hoc correction for multiple testing. Unpaired, 
two-tailed t-tests were used to analyze differences in the performances of different patient 
subgroups. Relevant changes in kinetic parameters for single subjects were evaluated by 
calculating the between-measurement variability (measurement error) within each double-
blind treatment period for each kinetic parameter. Relevant, drug-induced changes were 
defined as changes that exceeded or undershot the between-measurement variability by 2 




Of 61 patients, 44 participants were eligible for kinetic gait analysis. Whereas six patients were 
not included in the data analysis of the FAMPKIN trial,11 eleven participants were excluded 
from kinetic analysis (4 patients did not consistently walk within the pressure-sensitive area of 
the treadmill; 1 patient changed its walking assistance (handrails) between measurements; 6 
patients were excluded due to impaired foot clearance). The study population (n=44) was 49.8 
(± 9.6) years of age, consisted of 27 females (61%) and revealed a mean disease duration of 
12.4 (± 8.3) years (Table 1). Patients (21 relapsing-remitting, 4 primary-progressive and 19 
secondary-progressive MS) showed a mean disability of 4.6 ± 1.3 points in the expanded 
disability status scale (EDSS). Most PwMS walked unassisted on the treadmill (n=35), some 
patients were holding on to the handrails unilaterally (n=3) or bilaterally (n=6). Average 
treadmill walking speed was 0.61 ± 0.22 m/s. 
 
As for the total study population,11 maximal walking speed (T25FW) and endurance (6MWT) 
were significantly improved under PR-fampridine compared to placebo in the sub-population 
of patients undergoing kinetic assessment (n=44; p<0.0001 for T25FW and 6MWT; paired, 
two-tailed t-test).  
 
There were no overall drug-induced changes in any assessed kinetic parameter at the level 
of the total population (n=44) for the less- (LI) and more-impaired (MI) leg (Table 2). However, 
multiple changes in kinetic walking parameters as induced by PR-fampridine were observed 
at the single patient level. Patients revealing at least one relevant change in any kinetic 
parameter under PR-fampridine relative to placebo treatment (Figure 1B; see methods for 
definition of relevant change) were assigned to the kinetic adaptations (KA) group (n=8). 
Patients within this group showed heterogeneous changes in gait patterns: single limb support 
(mainly of the more-impaired leg) was enhanced by PR-fampridine in 4 patients, whereas pre-
swing phase during terminal stance phase was increased in 3 patients (Figure 1B). The 
majority of kinetic changes under PR-fampridine (13 of 18) resulted in enhanced ground 
reaction forces in patients’ more-impaired leg. 
Demographic data were not different between the NKA and KA subgroups (Table 1). 
Responders showed an enhanced disability status (EDSS: responders vs. non-responders: 
5.6 ± 1.1 vs. 4.4 ± 1.2; p = 0.0135; unpaired, two-tailed t-test) and a higher proportion of 
secondary progressive MS (MS types: responders vs. non-responders: p = 0.013; Pearson 
Chi-Square: 0.019). Both differences, however, were not significant after Bonferroni post-hoc 
correction for multiple testing.  
  
In a next step, we compared drug-induced effects on gait kinetics and clinical walking function 
in patients with (KA group; n=8) and without drug-induced kinetic adaptations (NKA group; 
n=36). Patients in the KA group revealed higher drug-induced improvements in maximal 
walking speed (T25FW) and walking endurance (6MWT) than patients without fampridine-
induced changes in walking kinetics (i.e. NKA group; T25FW: p=0.0135; 6MWT: p=0.0296; 





The present study demonstrated significant improvements in maximal walking speed (T25FW) 
and endurance (6MWT) upon double-blind treatment with PR-fampridine vs. placebo in the 
investigated sub-population of the FAMPKIN trial, thus confirming previous reports on the 
effects of PR-fampridine in gait-impaired PwMS.5,7,8,10,11 The primary aim of this study was to 
assess drug-induced changes in gait kinetics and to elucidate whether these locomotor 
adaptations might be a potential mechanisms underlying the well-documented positive drug-
effects on clinical walking performance. Mean kinetic parameters did not reveal drug-induced 
changes over the total population. On the single subject level, however, a subset of patients 
(8 of 44) revealed considerable drug-induced changes in gait kinematics. These kinetic 
changes were different across patients, possibly reflecting the heterogeneous nature of MS-
related symptoms that lead to gait impairments (e.g. spasticity, paresis, ataxia, sensory 
impairments etc.).21,23 This finding agrees with previous studies reporting that fampridine-
induced changes of different gait parameters rarely show group mean effects, as drug-induced 
gait adaptations are heterogenous across patients.5,11 The specific changes in kinetic 
parameters as induced by PR-fampridine might therefore depend on the individual impairment 
profile of each patient. The majority of patients demonstrating PR-fampridine induced changes 
in kinetic gait patterns (i.e. KA group) were diagnosed with secondary progressing MS and 
revealed higher EDSS scores compared to non-responding patients. This is in line with 
previous findings reporting that PwMS with higher levels of functional disability show enhanced 
responsiveness to PR-fampridine compared to mildly impaired PwMS.24-26 Superior positive 
drug responses in patients with severe MS-related impairments might be attributed to more 
pronounced axonal demyelination and neural damage in these patients. Given that fampridine 
enhances axonal conduction by blocking potassium channels along demyelinated axons,27,28 
patients with extensive demyelination (and higher disability) might benefit more from this 
treatment.   
PR-fampridine resulted in enhanced ground reaction forces primarily concerning patients’ 
more-impaired legs which might imply that changes in gait patterns are based on restoration 
of primary deficits instead of compensatory strategies. Three of eight patients within the KA 
group demonstrated enhanced vertical forces during the pre-swing phase under PR-
fampridine which might be indicative for improved gastrocnemius muscle function leading to 
faster walking speed in fampridine-treated PwMS.29 In multiple patients, we found significant 
increases in the produced forces during the single limb phases. Previous reports 
demonstrated that PwMS reveal prolonged periods of double limb support compared to 
healthy controls, probably to compensate for impaired dynamic stability during walking.30-32 
The significant increase of forces during single stance phase under PR-fampridine may 
indicate a shift from a pathological towards a more physiological gait pattern.33-35 
One major finding of this sub-study is that patients in the KA group showed greater fampridine-
induced improvements in the clinical walking tests compared to those patients that 
demonstrated no relevant changes in their gait kinetics. Thus, changes in gait kinetics may 
lead to improvements in walking performance as measured in clinical walking tests. This is in 
agreement with our earlier findings that fampridine-induced changes in 3D kinematic gait 
parameters correlated with enhanced walking performance in these patients.11 Compared with 
3D kinematic gait analysis, pressure-based gait analysis (e.g. GAITRite or instrumented 
treadmills) is less cost- and time-intense and widely used in clinics. The straightforward 
appliance of kinetic methodologies enables to investigate biomechanical changes as induced 
by PR-fampridine in larger patient cohorts, thus fostering the mechanistic understanding of 
how PR-fampridine enhances walking performance in gait-impaired PwMS.  
A limitation of this study is that a small subset of PwMS required handrail support during 
walking, which potentially confounds kinetic gait assessments. However, walking conditions 
(i.e. gait speed, handrail support) was kept constant for each individual across all longitudinal 
measurements, thus enabling an accurate and precise comparison of gait parameters under 
PR-fampridine and placebo. Walking barefoot during kinetic gait assessments might has been 
disabling for some patients, however, it enabled an accurate characterization of the pure, 
uncorrected walking pathology without compensation by external devices (e.g. shoes with 
orthopedic inlays, ankle braces). Due to the small sample size (particularly of subjects with 
kinetic adaptations), our findings need to be interpreted cautiously and require to be confirmed 
by future studies investigating the relation between qualitative and quantitative gait changes 
in response to PR-fampridine.  
 
Conclusion 
Our findings indicate that PR-fampridine leads to changes in gait kinetics in a subset of PwMS. 
Drug-induced adaptations in kinetics were associated with more pronounced improvements 
in clinical walking tests, suggesting that changes in the walking pattern may translate into 
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Figure 1. (A) After the screening visit (S), patients were treated with placebo (single-blind, 
run-in) for two weeks. Two 6-week double-blind treatment phases with PR-fampridine and 
placebo were separated by a 2-week washout phase (single-blind placebo treatment) between 
visits 6 and 7. Patients first treated with PR-fampridine (grey treatment arm) were afterwards 
treated with placebo and vice versa (cross-over design). During the 2 weeks follow-up, 
patients received no study drugs. Total duration of the study was 18 weeks. (B) Individual 
changes in kinetic gait parameters under PR-fampridine relative to placebo treatment on the 
single subject level. Changes exceeding (light grey) or undershooting (dark grey) the averaged 
variability between measurements (measurement error) ± 2 standard deviations are 
highlighted. (C)/(D) Changes in gait kinetics are related to improvements in clinical walking 
tests. Patients with changes in at least one kinetic parameter under PR-fampridine (i.e. KA 
group, n=8) showed a better response (improvement) to PR-fampridine than patients in the 
NKA group (n=36) in clinical walking tests (C: T25FW, D: 6MWT). Statistical analysis was 
performed by unpaired, two-tailed t-tests. Asterisk indicates p-value < 0.05. Abbreviations: 
AVG: average value over the respective gait phase; KA group: kinetic adaptations group; NKA 
group: no kinetic adaptations group; LI: less impaired; MI: more-impaired. SUM: cumulative 
value over the respective gait phase. 
 
Table 1. Demographic data of the study population. Data are shown for the total study 
population (n=44), for patients with fampridine-induced kinetic gait adaptations (KA group; 
n=8) and for patients without any changes in kinetic parameters (NKA; n=36). Abbreviations: 
EDSS: expanded disability status scale; KA; kinetic adaptations group; NKA; no kinetic 
adaptations group; PPMS: primary progressive multiple sclerosis; SD: standard deviation; 
SPMS: secondary progressive multiple sclerosis; RRMS: relapsing-remitting multiple 
sclerosis.    
 
Table 2. Fampridine-induced changes in kinetics over the total study population (n=44). 
Abbreviations: AVG: average value over the respective gait phase; SUM: cumulative value 





Table 1. Demographic data of the study population. Data are shown for the total study population 
(n=44), for kinetic responders (n=8) and for kinetic non-responders (n=36). Abbreviations: EDSS: 
expanded disability status scale; KA group: kinetic adaptations group; NKA group: no kinetic 
adaptations group; PPMS: primary progressive multiple sclerosis; SD: standard deviation; SPMS: 
secondary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis.    
  
Total cohort 
(n = 44) 
KA group  
(n = 8) 
NKA group 
(n = 36) 
Age, y, mean ± SD  49.6 ± 9.9 50.4 ± 8.9 49.4 ± 10.3 
Gender, number (%) Male 17 (39) 3 (38) 14 (39) 
 Female 27 (61) 5 (62) 22 (61) 
EDSS score, mean ± SD 
(range) 
 
4.6 ± 1.3 (2.5 – 6.5) 5.6 ± 1.1 (3.5 – 6.5) 4.4 ± 1.2 (2.5 – 6.5) 
Type of MS, number (%) RRMS 21 (48) 1 (13) 20 (56) 
 PPMS 4 (9) 0 4 (11) 
 SPMS 19 (43) 7 (87) 12 (33) 
Disease duration, y from 
diagnosis, mean ± SD  
 











Table 2. Fampridine-induced changes in kinetics over the total study population (n=44). Differences 
between kinetic parameters under PR-fampridine and placebo were compared by paired, two-tailed t-
tests. Abbreviations: AVG: average value over the respective gait phase; SUM: cumulative value over 


















single stance AVG  0.909 0.917 0.105 0.914 0.924 0.053 
single stance SUM  35.587 35.651 0.905 37.437 37.531 0.891 
load AVG  0.491 0.495 0.315 0.537 0.536 0.856 
load SUM 14.213 14.507 0.317 16.212 16.07 0.597 
pre-swing AVG  0.471 0.479 0.079 0.499 0.503 0.465 
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increase > error + 2 SD
decrease > error + 2 SD
